| 116.3 0 (0%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Horizon Therapeutics Public Limited Company operates as a biotechnology enterprise, primarily concentrating on the identification, refinement, and commercialization of pharmaceutical products designed to address significant medical needs for individuals afflicted by rare, autoimmune, and severe inflammatory conditions. The company's operations are divided into two principal divisions: Orphan and Inflammation. Its extensive product lineup features twelve distinct medications, targeting therapeutic areas such as rare diseases, gout, ophthalmic conditions, and various forms of inflammation. Among its marketed offerings are TEPEZZA (an intravenous infusion), KRYSTEXXA (also administered intravenously), the oral liquid RAVICTI, PROCYSBI (available as oral delayed-release capsules and granules), the subcutaneous injectable ACTIMMUNE, BUPHENYL (oral tablets and powder), the inhaled solution QUINSAIR, and the intravenous injection UPLIZNA. Furthermore, the company's portfolio includes PENNSAID (a topical solution), DUEXIS (oral tablets), RAYOS (delayed-release oral tablets), and VIMOVO (delayed-release oral tablets). Horizon Therapeutics maintains strategic partnerships with several entities, including HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. Founded in 2005, the company, originally known as Horizon Pharma Public Limited Company, rebranded to its current name in May 2019. Its global headquarters are situated in Dublin, Ireland, complemented by additional offices located in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.
Fri, 01 Sep 2023
Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition - Business Wire
Sun, 08 Jan 2023
Horizon Pharma PLC (HZNP) Share Price Today | Horizon Pharma PLC (HZNP) Live NSE/BSE - Value Research
Mon, 12 Dec 2022
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc - PR Newswire
Tue, 29 Nov 2022
Horizon Therapeutics plc Confirms Preliminary Discussions Regarding Potential Offer - Business Wire
Thu, 10 Feb 2022
Horizon Therapeutics plc Named Title Partner of the Irish Open - Business Wire
Wed, 03 Nov 2021
Horizon Therapeutics plc Announces Chief Financial Officer Succession Plan - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|